11 results about "Viral illness" patented technology

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for treating respiratory viral illnesses, such as COVID-19.

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

The invention relates to the technical field of biology, in particular to a porcine reproductive and respiratory syndrome virus subunit vaccine. Through bioinformatics analysis and experimental verification, the antigen protein with excellent immunogenicity is obtained through screening, and the amino acid sequence of the antigen protein is shown as SEQ ID NO: 1. The subunit vaccine constructed on the basis of the protein can effectively induce mice to generate high-level neutralizing antibodies, the effect of the subunit vaccine is remarkably better than that of commercial control vaccines, the mice can be stimulated to generate strong humoral immunity and cellular immunity at the same time, and the induced immune response type is mainly Th2 type. Further research shows that the antigen protein and the virus structural protein E + M are combined for immunization, and the immune effect of the structural protein can be remarkably enhanced. The subunit vaccine developed by the invention provides a new thought for research and development of novel vaccines for resisting PRRSV and other viral diseases.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. Relates to a compound shown in a general formula (I), a preparation method thereof and a pharmaceutical composition containing the compound. The invention also relates to the application of the compound in preparation of medicines for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases and the like. The invention also relates to the application of the medicine for treating diseases related to cell death or cardiovascular diseases. Wherein each substituent in the general formula (I) is as defined in the specification.

The present invention relates to an antagonistic small molecule compound having a function of inhibiting an endosome toll-like receptor (TLR), and more particularly to: a small molecule compound for inhibiting a TLR3 / 7 / 8 / 9 signaling pathway; a composition for inhibiting a toll-like receptor comprising the small molecule compound; and a composition for preventing or treating an autoimmune disease, an inflammatory disease, or a viral disease. The compound according to the present invention shows very significant results in a systemic lupus erythematosus animal model, which not only prevents TNF-α secretion induced by poly I:C (TLR3 agonist), imiquimod (TLR7 agonist), TL8-506 (TLR8 agonist), or ODN2395 (TLR9 agonist), but also inhibits the production of inflammatory cytokines. This indicates that the compound can also be used for preventing or treating TLR3, TLR7, TLR8, or TLR9-related autoimmune diseases, inflammatory diseases, and viral diseases.

An estrosphere preparation comprising an ester phase and an aqueous phase characterised in that the ester phase comprises α-linolenic acid ethyl ester, or a mixture of α-linolenic acid ethyl ester with one or more components selected from the group comprising polyunsaturated fatty acids ethyl esters (PUFA ethyl esters) or triglycerides, ethanol, and emulsifier, in a weight ratio of between 2:0.5:1 and 8:2:1, respectively, and the aqueous phase comprises water with glycerol at a final concentration of 2.25% by weight, wherein the weight ratio of α-linolenic acid ethyl ester, or of the mixture of α-linolenic acid ethyl ester with one or more components to ethanol, emulsifier and water is between 2:0.5:1:45 and 8:2:1:45, respectively. A method for producing such an estrosphere preparation. Said preparation for use in the treatment of cancer and viral diseases.

The present invention provides methods, assays and kits for evaluation and assessment of IP-10 (CXCL10) expression, particularly IFN induction of IP-10, to determine the presence of inborn errors of the Type I IFN or Type II IFN response pathway and / or auto-antibodies directed against, and particularly neutralizing, Type I IFNs or Type II IFNs in a patient. The methods, assays and kits including for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients, particularly including those who develop vaccine-associated disease. Identification of inborn errors of the Type 1 IFN response pathyway and / or auto-antibodies directed against, and particularly neutralizing, Type I IFNs are associated with severe viral illness, including COVID-19 disease, and vaccine-associated disease, particularly with live attenuated virus vaccines, particularly including yellow fever vaccines, as well as arboviral diseases, including WNV and TSE encephalitis.

This invention provides dual-target inhibitors of PD-1 / PD-L1 and JAK, their preparation methods, and uses, including compounds with the structure shown in Formula I and their pharmaceutically acceptable salts, solvates, hydrates, prodrugs, or tautomers. The compounds of this invention are the first publicly disclosed dual-target inhibitors of PD-1 / PD-L1 and JAK, capable of acting on both PD-1 / PD-L1 and JAK, exhibiting good inhibitory activity against both PD-1 / PD-L1 and JAK proteins, and significantly inhibiting tumor growth. These compounds can be widely used in the preparation of dual-target inhibitors of PD-1 / PD-L1 and JAK, as well as in the preparation of drugs for the treatment and / or prevention of cancer, inflammation, and viral diseases, and have further research, development, and clinical translational value.

The pyrimidine derivatives as shown in a formula (I-1), a formula (I-2), a formula (II-1) or a formula (II-2) or stereoisomers, tautomers, isotope derivatives, hydrates, solvates, prodrugs and pharmaceutically acceptable salts thereof can be used as effective TLR7 and / or TLR8 receptor agonists, and have the characteristics of good selectivity, high activity and good safety; meanwhile, the invention provides a preparation method and a pharmaceutical composition of the pyrimidine derivative. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing or treating infectious diseases, respiratory diseases, immune-related diseases, viral diseases or tumors.